Method for synthesizing 4-Deoxygadusol in vitro

The synthesis of 4-Deoxygadusol by using Nostoc linkia NIES-25's MAAs synthetase MysA3 and MysB3 was catalyzed through the multi-enzyme cascade of Nostoc linkia NIES-25, which solved the problem of unknown MAAs synthesis pathway and achieved efficient synthesis and research progress of MAAs.

CN118931976AInactive Publication Date: 2024-11-12SHANDONG HECHENG BIOTECHNOLOGY CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411229063.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-03
Publication Date
2024-11-12
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

It is difficult to effectively synthesize and study 4-Deoxygadusol, a key precursor substance for MAAs synthetase, resulting in unknown synthesis pathways of MAAs, affecting its yield and research difficulty in organisms.

Method used

The MAAs synthetase MysA3 and MysB3 from the algal strain Nostoc linkia NIES-25 were used for in vitro multi-enzyme cascade reaction, and sedan heptol-7-phosphate was used as the substrate to successfully synthesize 4-Deoxygadusol.

Benefits of technology

Synthesis of 4-Deoxygadusol in vitro provides a new way for subsequent MAAs synthesis, reducing the difficulty of enzyme purification and structural research, and improving the yield and research efficiency of MAAs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118931976A_ABST
    Figure CN118931976A_ABST
Patent Text Reader

Abstract

The invention provides a method for synthesizing 4-Deoxygadusol in vitro, which belongs to the technical field of biology, and is characterized in that S7P (sedoheptulose-7-phosphoric acid) is used as a substrate, MAAs synthetases MysA3 and MysB3 from an algae strain Nostoc linkia NSES-25 are used as catalytic enzymes, and the 4-Deoxygadusol is catalytically synthesized in vitro; wherein the nucleotide sequences of the coding gene MysA3 and the coding gene MysB3 are respectively as shown in SEQ ID NOs.5 to 6. According to the method, the synthesis precursor substance 4-Deoxygadusol of the MAAs is successfully synthesized through in-vitro catalysis, and the method has important significance for exploring a new MAAs synthesis route.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of biotechnology, in particular to a method for synthesizing 4-Deoxygadusol in vitro. Background Art

[0002] The ozone layer is only 0.3cm thick in the earth's atmosphere. The ozone layer absorbs almost all UV-C and about 90% of UV-B radiation that reaches the atmosphere. However, the large-scale use of halogenated organic compounds such as chlorofluorocarbons and halons in modern industrial production and people's lives, coupled with the extreme climate in the polar regions, has led to serious damage to the ozone layer. The destruction of the ozone layer has increased the UV-B radiation reaching the surface. A large number of studies have confirmed that UV-B radiation can cause varying degrees of damage to organisms. High-intensity UV-B radiation can directly damage DNA, proteins, lipids and pigments in cells, and can also stimulate active substances that produce free radicals, which can further cause greater damage to cells.

[0003] Algae living in Antarctica have developed a series of defense mechanisms to cope with high-intensity UV-B radiation, among which mycosporine-like amino acids (MAAs) are important UV defense substances. MAAs have been found in many seaweeds. Short-wavelength radiation stimulates the synthesis of MAAs, which mainly play a role in UV protection and growth regulation in seaweed. (Gracilaria cornea ) found that MAAs have high stability against environmental stress factors such as UV-B and high temperature. In addition to good anti-ultraviolet radiation activity, Xu Zhiheng, He Qingmei and others found that MAAs in Porphyra and Gracilaria also have good antioxidant activity. Good anti-ultraviolet radiation and antioxidant activity make natural ultraviolet absorbing compounds MAAs can be used as UV blockers in skin care products. Studies have shown that the anti-ultraviolet effect of a face cream with 5% MAAs (mainly containing Prophyra-334 and Shinorine) is equivalent to that of a 1% UV-A filter and a 4% UV-B filter, far exceeding the ultraviolet protection people need for daily life. However, the content of MAAs synthase in organisms is extremely low, which makes it extremely difficult to directly isolate and purify MAAs synthase from organisms and conduct research on its structure, functional activity and mechanism of action.

[0004] The basic skeleton of MAAs is cyclohexenone. 4-deoxygadusol (4-DG) is the synthetic precursor of MAAs, which can undergo condensation reactions with different amino acids to produce various types of MAAs. At present, there has been no specific research and reports on the synthesis pathway and method of 4-deoxygadusol.

[0005] The in vitro multi-enzyme cascade reaction system is a system in which multiple enzymes or coenzymes act synergistically under specific conditions to perform a variety of complex biotransformation processes, thereby achieving efficient production of target products. It has significant advantages such as fast reaction rate, high selectivity, and easy operation, and shows great application prospects in the field of biosynthesis. In order to further optimize the yield of MAAs, the present invention attempts for the first time to use an in vitro multi-enzyme cascade reaction system to synthesize 4-Deoxygadusol in vitro, providing a new approach for the subsequent synthesis of MAAs. Summary of the invention

[0006] The present invention provides a method for synthesizing 4-Deoxygadusol in vitro, using Nostoc linkia MysA, the MAAs synthase of NIES-25 3 、MysB 3 As a catalytic enzyme, S7P substrate was catalyzed and the synthetic precursor of MAAs, 4-Deoxygadusol, was successfully synthesized in vitro, which is of great significance for exploring new synthetic pathways of MAAs.

[0007] The technical solution of the present invention is as follows: A method for synthesizing 4-Deoxygadusol in vitro is to use sedoheptulose-7-phosphate as a substrate and MysA 3 、MysB 3 It is a catalytic enzyme that catalyzes the synthesis of 4-Deoxygadusol in vitro; Among them, the MysA 3 Coding genes sA 3 The nucleotide sequence of MysB is shown in SEQ ID NO.5. 3 Coding genes mysB 3 The nucleotide sequence is shown in SEQ ID NO.6.

[0008] Preferably, the method for synthesizing 4-Deoxygadusol in vitro comprises the following steps: (1) preparing sedoheptulose-7-phosphate solution; (2) Configuration containing MysA 3 and MysB 3 Complex enzyme solution; (3) Add the complex enzyme solution of step (2) to the sedoheptulose-7-phosphate solution of step (1), and react under shaking at 35-37° C. for 4-5 hours to obtain a reaction solution containing 4-deoxygadusol.

[0009] Preferably, the concentration of the sedoheptulose-7-phosphate solution in step (1) is 4-6 mM.

[0010] Preferably, the preparation method of the complex enzyme solution in step (2) is: adding MysA with a concentration of 1-2 mg / mL 3 The enzyme solution and MysB at a concentration of 1.6~2.2mg / mL 3 The enzyme solutions were mixed in a volume ratio of 4:(2.9-3.1) to obtain a composite enzyme solution.

[0011] Preferably, the volume ratio between the sedoheptulose-7-phosphate solution and the complex enzyme solution in step (3) is 1:(0.9-1.1).

[0012] Preferably, the MysA 3 、MysB 3 The preparation method comprises the following steps: S1, sA 3 , mysB 3 The vectors are respectively introduced into Escherichia coli to obtain recombinant Escherichia coli; S2, inoculate the recombinant E. coli in LB liquid medium for activation culture at 35-37°C, inoculate the activated recombinant E. coli culture liquid into new LB liquid medium at a ratio of 1-3% (v / v), and culture until OD 600 is 0.5-0.7, then add IPTG with a final concentration of 0.1-0.5 mM, induce culture at a culture temperature of 25-30°C for 20-36 hours to obtain fermentation broth; S3, purify the protein in the fermentation broth to obtain MysA 3 、MysB 3 .

[0013] Preferably, the vector in step S1 is a pET28b plasmid.

[0014] Preferably, the activation culture conditions in step S2 are: inoculating the recombinant E. coli into LB liquid culture medium and performing activation culture at 35-37° C. for 1-10 hours.

[0015] Preferably, the induction culture time in step S2 is 20 to 36 hours.

[0016] Preferably, the purification method in step S3 is nickel column purification.

[0017] Beneficial effects: The present invention combines three sets of key enzyme genes sA , mysBThe recombinant E. coli were cloned and constructed respectively, and the protein expression effect of each gene was detected to screen out the two key enzymes MysA with the highest expression level. 3 、MysB 3 After obtaining the key enzyme with high purity, the biosynthetic pathway of 4-Deoxygadusol was followed by the use of MysA with sedoheptulose-7-phosphate as the starting substrate. 3 、MysB 3 As a catalytic enzyme, a one-pot multi-enzyme cascade reaction was carried out to prepare 4-Deoxygadusol, which is of great significance for exploring new synthetic pathways for MAAs. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 MysA 3 、MysB 3 The protein expression of Figure 2 MysA 3 、MysB 3 Protein purification status; Figure 3 Schematic diagram of the metabolic pathway of 4-Deoxygadusol in the in vitro multi-enzyme cascade reaction; Figure 4 HPLC and LC-MS detection spectra of substrates and products of in vitro multi-enzyme cascade reactions. DETAILED DESCRIPTION

[0019] The following is explained in conjunction with specific embodiments: (1) Source of experimental materials: pET28b, E. coli XL1-Blue, E. coli BL21: All are conventional commercial products, sourced from the Biological Laboratory of Qilu University of Technology.

[0020] Sedoheptulose-7-phosphate (S7P) was purchased from Cayman Chemical Company.

[0021] (2) Preparation of culture medium and main reagents used in the following examples: LB liquid medium: 10 g / L peptone, 5 g / L yeast extract, 10 g / L sodium chloride.

[0022] LB solid medium: 10 g / L peptone, 5 g / L yeast extract, 10 g / L sodium chloride, 15 g / L agar.

[0023] Binding buffer: 20 mM PB, 0.5 M NaCl, pH 7.4.

[0024] Wash buffer: 20 mM PB, 0.5 M NaCl, 20 mM imidazole, pH 7.4.

[0025] Elution buffer: 20 mM PB, 0.5 M NaCl, 500 mM imidazole, pH 7.4.

[0026] Staining solution: 100 mL glacial acetic acid, 200 mL anhydrous ethanol, 1.0 g Coomassie brilliant blue.

[0027] Decolorizing solution: 100 mL glacial acetic acid, 250 mL anhydrous ethanol, 700 mL distilled water.

[0028] PBS buffer: 8.0 g NaCl, 0.2 g KCl, 1.44 g Na 2 HPO 4 , 0.24 g KH 2 PO 4 , 1000 mL of distilled water, and HCl to adjust the pH to 7.4.

[0029] SDS PAGE loading buffer: 1.25 mL 1 M Tris-HCl buffer, 0.5 g sodium dodecyl sulfate, 0.025 g bromophenol blue, 2.5 mL glycerol, 0.25 mL β-mercaptoethanol, and ddHO. 2 0 to 25mL.

[0030] Example 1: Construction of single enzyme plasmid 1. MAAs Synthesis Gene The inventors selected three MAAs synthetic gene clusters, from Nostoc punctiforme ATCC 29133, Anabaena variabilis ATCC 29413, Nostoc linkia NIES-25, sent the six key enzyme genes in the MAAs synthesis gene cluster to Paisono Biotech for codon optimization and gene synthesis.

[0031] Among them, the information of 6 key enzyme genes is as follows: sA 1 , mysB 1 : From Nostoc punctiforme The MAAs synthesis gene cluster in ATCC 29133 is gene cluster 1, and its nucleotide sequences are shown in SEQ ID NOs. 1~2 respectively.

[0032] sA 2 , mysB 2 : From Anabaena variabilisThe MAAs synthesis gene cluster in ATCC 29413 is gene cluster 2, and its nucleotide sequences are shown in SEQ ID NOs. 3~4 respectively.

[0033] sA 3 , mysB 3 : From Nostoc linkia The MAAs synthesis gene cluster in NIES-25 is gene cluster 3, and its nucleotide sequences are shown in SEQ ID NOs.5~6 respectively.

[0034] 2. Construction of recombinant plasmid The pET28b plasmid was used N I and XOt I was subjected to double enzyme digestion and purified to obtain a pET28b vector fragment; Using ClonExpress Ⅱ one-step cloning kit, the pET28b vector fragment was connected with the above six key enzyme genes respectively to obtain six recombinant plasmids.

[0035] 3. Construction of recombinant Escherichia coli The six recombinant plasmids were transformed into E. coli In XL1-Blue, the specific operation is as follows: Competent cells E. coli XL1-Blue was taken out of the ultra-low temperature refrigerator and placed on ice for later use; 10 μL of the recombinant plasmid was drawn and added to the competent cells, and the mixture was mixed by blowing gently, and then placed on ice for 30 minutes, and then heat-shocked in a 42°C water bath for 90 seconds, and immediately placed on ice for 2 minutes to obtain the transformation solution. 900 μL of LB liquid culture medium was added to the transformation solution, and the cells were revived on a shaker at 37°C for 1 hour, centrifuged at 6000 rpm for 3 minutes, and 500 μL of the supernatant was drawn off. The remaining supernatant and the bacteria were gently mixed to obtain a bacterial suspension, and 100 μL of the bacterial suspension was drawn and applied to a LB solid culture medium containing 50 μg / mL Kan and 50 μg / mL Amp, and cultured at 37°C for 12 hours until a single colony grew.

[0036] Single colonies were picked for preliminary verification by colony PCR, and then plasmids were extracted for sequencing. The recombinant plasmids that were successfully sequenced were transformed into E. coli In BL21, the transformation method was the same as above, and 6 recombinant E. coli strains were obtained, namely: E. coli BL21 / pET28b- sA 1 , E. coli BL21 / pET28b- mysB 1 , E. coli BL21 / pET28b- sA2 , E. coli BL21 / pET28b- mysB 2 , E. coli BL21 / pET28b- sA 3 , E. coli BL21 / pET28b- mysB 3 .

[0037] Example 2: Enzyme expression and purification 1. Enzyme Expression The six recombinant E. coli strains in Example 1 were inoculated into LB liquid culture medium for activation culture at 37°C for 1 h. The activated bacterial solution was inoculated into LB liquid culture medium containing 50 μg / mL Kan at a ratio of 1% (v / v) and cultured until OD 600 is 0.6; add IPTG with a final concentration of 0.2mM, induce culture at 25℃ for 20h to obtain fermentation broth.

[0038] The fermentation broth was centrifuged at 10,000 rpm for 5 min, the bacterial precipitate was collected, washed twice with PBS buffer and resuspended, and the resuspended liquid was crushed using an ultrasonic crusher (ultrasonication for 4 s and pause for 4 s), with a power of 400 W and ultrasonication for 20 min.

[0039] After the ultrasound is finished, the liquid after ultrasound is aspirated and added into SDS PAGE Loading buffer to prepare a whole-cell sample; the liquid after ultrasound is centrifuged at 10000 rpm for 10 min, and SDS PAGE Loading buffer is added into the supernatant to prepare a whole-cell sample.

[0040] The protein expression in whole cell samples and whole intracellular samples was analyzed by 12% SDS-PAGE. Figure 1 As shown, lane M is 180kDa Prestained Protein Marker, and lanes 1 and 2 are blank controls. E. coli Schematic diagram of whole cell and intracellular protein expression of BL21, lanes 3 to 6 are MysA 1 、MysB 1 Whole cell and intracellular protein expression results, lanes 7 to 10 are MysA 2 、MysB 2 Whole cell and intracellular protein expression results, lanes 11 to 14 are MysA 3 、MysB 3 Whole cell and intracellular protein expression results.

[0041] Depend on Figure 1 All proteins were soluble, with no or a small amount of inclusion bodies, indicating that the selected induction conditions were appropriate. 3 The expression level was slightly higher than that of MysA 2 ,MysB 2 A small amount of inclusion bodies were produced, MysB 3 The expression level is the highest. 3 、MysB 3 The protein expression effect is the best. From the perspective of protein expression level, Nostoc linkia The synthetic gene cluster of MAAs derived from NIES-25 has a stronger production capacity and its effect is better than Nostoc punctiforme ATCC 29133 and Anabaena variabilis ATCC 29413.

[0042] 2. Enzyme Purification Recombinant Escherichia coli E. coli BL21 / pET28b- sA 3 , E. coli BL21 / pET28b- mysB 3 The activated culture was carried out at 37°C for 1 h, and the activated bacterial solution was inoculated into LB liquid medium containing 50 μg / mL Kan at a ratio of 1% (v / v) and cultured until OD 600 is 0.6; add IPTG with a final concentration of 0.2mM, induce culture at 25℃ for 20h to obtain fermentation broth.

[0043] The fermentation liquid was centrifuged at 10,000 rpm for 5 min, the bacterial precipitate was collected, washed twice with PBS buffer and resuspended, and the resuspended liquid was crushed using an ultrasonic crusher (ultrasonication for 4 s and pause for 4 s), power 400w, ultrasonication for 20 min. The liquid after ultrasonication was centrifuged at 10,000 rpm for 10 min, and SDS PAGE Loading buffer was added to the supernatant to prepare the whole intracellular sample.

[0044] Follow these steps to perform nickel column purification of intracellular samples: (1) Sample preparation: Filter the intracellular sample with a 0.22 μm filter membrane; (2) Water washing: Wash the resin with 5 mL of pure water; (3) Equilibration: Equilibrate with 5 mL of binding buffer; (4) Sample loading: Load the sample, incubate in the nickel column for 30 min, and collect the flow-through; (5) Washing: Wash with 10 mL of washing buffer; (6) Elution: Elute with 5 mL of elution buffer and collect the eluate.

[0045] The dialysis bag was softened by soaking in pure water in advance, and the collected eluate was transferred to the dialysis bag. The molecular weight of the dialysis bag was 14kD. The two ends were clamped with plastic clips and dialyzed at 4°C for 6 hours in PBS buffer, during which the dialysis solution was replaced. The dialyzed protein was added to SDS PAGE Loading buffer to prepare a protein sample, and the protein expression was analyzed by 12% SDS-PAGE, in which the staining solution was used for 3 hours, the decolorizing solution was used for 1 hour, and the decolorizing solution was replaced 3 times during the decolorization period.

[0046] The purified enzyme was analyzed by SDS-PAGE for purity. Figure 2 As shown, lane M is 180kDa Prestained Protein Marker, and lanes 1 and 2 are MysA 3 、MysB 3 Protein purification results. Figure 2 The purified MysA 3 、MysB 3 The molecular weights of MysA and 3 Enzyme solution, MysB 3 The protein concentrations in the enzyme solutions were 1.001 mg / mL and 1.676 mg / mL, respectively.

[0047] Example 3: In vitro synthesis of 4-Deoxygadusol by multi-enzyme cascade reaction The purified MysA 3 、MysB 3 4-Deoxygadusol was synthesized in vitro by an in vitro multi-enzyme cascade reaction. The synthesis diagram is shown in Figure 3 As shown, specifically: the substrate S7P (Sedoheptulose-7-phosphate) generates 4-Deoxygadusol under the action of MysA and MysB.

[0048] The in vitro multi-enzyme cascade reaction is as follows: (1) Using ultrapure water as solvent, prepare a 5 mM S7P solution.

[0049] (2) MysA with a protein concentration of 1.001 mg / mL 3 Enzyme solution and MysB with a protein concentration of 1.676 mg / mL 3 The enzyme solutions were mixed in a volume ratio of 4:3 to obtain a composite enzyme solution.

[0050] (3) Experimental group: 1 mL of S7P solution and 1 mL of complex enzyme solution were shaken and reacted at 37°C for 4 h to obtain a reaction solution; Blank control group: Different from the experimental group, MysA 3 Enzyme solution and MysB 3 The enzyme solution was boiled for 5 minutes to inactivate it and prepared into a composite enzyme solution, while other conditions remained unchanged.

[0051] (4) After the reaction is completed, the reaction solution is heated with boiling water for 10 minutes to terminate the reaction, and then centrifuged at 10000 rpm for 10 minutes. The supernatant is taken and filtered using a 0.22 μm filter membrane to obtain a sample. The product in the sample is tested by HPLC.

[0052] HPLC test results are as follows Figure 4 As shown, Figure A is the HPLC detection spectrum of substrate S7P, and Figure B is the HPLC detection spectrum of MysA after inactivation. 3 、MysB 3 Figure 1 is the HPLC detection spectrum of the samples in the blank control group, Figure 2 is the HPLC detection spectrum of the samples in the experimental group, and Figure 3 is the secondary mass spectrum and structure of 4-Deoxygadusol.

[0053] Depend on Figure 4 It can be obtained that the elution time of the substrate S7P in Figure A is 5.08min, and a very small substrate peak appears at around 5.213min in Figure C. The other peaks in Figures C and D are very close to the peak time in Figure B, which indicates that most of the impurities in the blank control group and the experimental group samples are caused by the enzyme's own existence system (PBS buffer); a new substance is generated at 10.428min in Figure D, which is identified as the target substance 4-Deoxygadusol by LC-MS (Figure E). The result shows that 4-Deoxygadusol was successfully synthesized through the above-mentioned in vitro multi-enzyme cascade reaction system.

[0054] In summary, the present invention is based on the algae strain Nostoc linkia MysA, the MAAs synthase of NIES-25 3 、MysB 3 As a catalytic enzyme, 4-Deoxygadusol, a synthetic precursor of MAAs, was successfully synthesized in vitro by carrying out a one-pot multi-enzyme cascade reaction, which is of great significance for exploring new synthetic pathways of MAAs.

Claims

1. A method for synthesizing 4-Deoxygadusol in vitro, characterized in that: The method uses sedoheptulose-7-phosphate as substrate and MysA3 and MysB3 as catalytic enzymes to catalyze the synthesis of 4-Deoxygadusol in vitro. Among them, the MysA3 encoding gene sA The nucleotide sequence of 3 is shown in SEQ ID NO.5, and the MysB3 encoding gene mysB The nucleotide sequence of 3 is shown in SEQ ID NO.

6.

2. The method according to claim 1, characterized in that The steps include: (1) preparing sedoheptulose-7-phosphate solution; (2) preparing a complex enzyme solution containing MysA3 and MysB3; (3) Add the complex enzyme solution of step (2) to the sedoheptulose-7-phosphate solution of step (1), and shake the mixture for reaction at 35-37° C. for 4-5 h to obtain a reaction solution containing 4-deoxygadusol.

3. The method according to claim 2, characterized in that The concentration of the sedoheptulose-7-phosphate solution in step (1) is 4-6 mM.

4. The method according to claim 2, characterized in that The preparation method of the composite enzyme solution in step (2) is as follows: MysA3 enzyme solution with a concentration of 1-2 mg / mL and MysB3 enzyme solution with a concentration of 1.6-2.2 mg / mL are mixed in a volume ratio of 4:(2.9-3.1) to obtain the composite enzyme solution.

5. The method according to claim 2, characterized in that The volume ratio of the sedoheptulose-7-phosphate solution to the complex enzyme solution in step (3) is 1:(0.9-1.1).

6. The method according to claim 1, characterized in that The preparation method of MysA3 and MysB3 comprises the following steps: S1, sA 3. mysB 3 are respectively introduced into Escherichia coli to obtain recombinant Escherichia coli; S2, inoculate the recombinant E. coli in LB liquid medium for activation culture at 35-37°C, inoculate the activated recombinant E. coli culture liquid into new LB liquid medium at a ratio of 1-3% (v / v), and culture until OD 600 is 0.5-0.7, then add IPTG with a final concentration of 0.1-0.5 mM, and induce culture at a culture temperature of 25-30°C for 20-36 hours to obtain a fermentation broth; S3, purifying the proteins in the fermentation broth to obtain MysA3 and MysB3 respectively.

7. The method according to claim 6, characterized in that The vector in step S1 is pET28b plasmid.

8. The method according to claim 6, characterized in that The activation culture conditions in step S2 are: inoculating the recombinant E. coli into LB liquid culture medium and performing activation culture at 35-37° C. for 1-10 hours.

9. The method according to claim 6, characterized in that The induction culture time in step S2 is 20 to 36 hours.

10. The method according to claim 6, characterized in that The purification method described in step S3 is nickel column purification.

Citation Information

Cited By

  • Streptomyces recombinant engineering strain for producing mycosporine-like metabolite as well as construction method and application of streptomyces recombinant engineering strain

    CN119193457A